Patents by Inventor Nathan Moerke

Nathan Moerke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phospho-Rab antibodies, assays and methods of use thereof
    Patent number: 11661461
    Abstract: In one aspect, antibodies that specifically bind to a phosphorylated Rab protein are provided. In some embodiments, the antibody is a monoclonal antibody that specifically binds to a phosphorylated human Rab10 protein and recognizes an epitope within or comprising the sequence AGQERFH(pT)ITTSYYR (SEQ ID NO:123). In some embodiments, the antibody is a monoclonal antibody that specifically binds to a phosphorylated human Rab8a protein and recognizes an epitope within or comprising the sequence QERFR(pT)ITTAY (SEQ ID NO:125). Methods and materials for detecting LRRK2 and Rab protein are also provided.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: May 30, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Jason C. Dugas, Anastasia Henry, Sarah Huntwork-Rodriguez, Michael T. Maloney, Nathan Moerke, Ella Negrou, Xiang Wang
  • PHOSPHO-RAB ANTIBODIES, ASSAYS AND METHODS OF USE THEREOF
    Publication number: 20210147573
    Abstract: In one aspect, antibodies that specifically bind to a phosphorylated Rab protein are provided. In some embodiments, the antibody is a monoclonal antibody that specifically binds to a phosphorylated human Rab10 protein and recognizes an epitope within or comprising the sequence AGQERFH(pT)ITTSYYR. In some embodiments, the antibody is a monoclonal antibody that specifically binds to a phosphorylated human Rab8a protein and recognizes an epitope within or comprising the sequence QERFR(pT)ITTAY. Methods and materials for detecting LRRK2 and Rab protein are also provided.
    Type: Application
    Filed: June 15, 2018
    Publication date: May 20, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Jason C. Dugas, Anastasia Henry, Sarah Huntwork-Rodriguez, Michael T. Maloney, Nathan Moerke, Ella Negrou, Xiang Wang
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200277373
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody increases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody decreases levels of sTREM2. In some embodiments, the antibody enhances TREM2 activity. In some embodiments, the antibody inhibits TREM2 activity.
    Type: Application
    Filed: September 14, 2018
    Publication date: September 3, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Hang Chen, Gilbert Di Paolo, Rui Hao, Joseph W. Lewcock, Nathan Moerke, Alicia A. Nugent, Rishi Rakhit, Ju Shi, Rinkan Shukla, Ankita Srivastava, Bettina Van Lengerich, Yin Zhang
  • Regulation of protein synthesis
    Publication number: 20100144805
    Abstract: A composition and method for inhibiting proliferation of a tumor cell compared to a non-tumor cell. Also described are methods of screening for a composition that inhibits cap-dependent translation compared to cap-independent translation of proteins.
    Type: Application
    Filed: January 20, 2006
    Publication date: June 10, 2010
    Inventors: Gerhard Wagner, Michael Chorev, Nathan Moerke, Huseyin Aktas, José Halperin